Related Experiment Videos

COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?

Wallace J Brownlee1

  • 1Department of Neuroinflammation, Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, London, UK/National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|August 9, 2020
PubMed
Abstract

No abstract available in PubMed .

Keywords:
COVID-19multiple sclerosis

Related Concept Videos